BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Newcastle Hospitals Clinical Skills Academy - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://skillsacademy.newcastle-hospitals.nhs.uk
X-WR-CALDESC:Events for Newcastle Hospitals Clinical Skills Academy
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250204T084500
DTEND;TZID=Europe/London:20250204T160000
DTSTAMP:20260406T051058
CREATED:20241025T115146Z
LAST-MODIFIED:20241204T130225Z
UID:10000093-1738658700-1738684800@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Methods of Wound Debridement - February 2025
DESCRIPTION:This two-day course held on Tuesday 4th February 2025 and Wednesday 5th February 2025 will teach the different methods of wound debridement\, with a special focus on conservative sharp debridement. \nIt is facilitated by the Newcastle Hospitals’ Tissue Viability Team with guest speakers from the specialties of Dermatology\, Plastics\, Podiatry as well as a physiology and anatomical expert from Sunderland University. \nThe objective is to provide a summary of the professional accountability and legal issues associated with wound debridement alongside the theoretical basis to justify the decision-making process in the selection of the appropriate debriding agents. \nA pre-course workbook will be sent 4 weeks prior to the face to face study days via email which will need to be completed and submitted on Day 1 of the course. \nA course pack will be provided on the first day\, which will include the course handbook\, the notes from the presentations and other useful information. \nLearning outcomes\nDebridement describes the removal of dead or devitalised tissue\, in particular matter and foreign bodies from a wound bed and is generally accepted as a necessary precursor to the formation of new tissue (EWMA 2013). \nAt the end of this two-day course delegates will be able to: \n\nExplore human anatomy and physiology including in depth revision of the buttock\, sacrum and lower limbs\nIdentify normal and abnormal wound healing including when biopsy may be required\nExamine wound debridement techniques and identify the differences between conservative sharp debridement and surgical debridement\nDemonstrate clinical knowledge and practice skills required to perform safe and effective wound debridement techniques\, practiced in laboratory conditions\nUse analytic skills to appraise the available literature related to wound debridement\nOpportunity to develop academic writing at Level 7.\n\nCourse lead\nDr Fania Pagnamenta\, Clinical Academic Nurse Consultant has a real passion for tissue viability and wound care management and has years of experience supporting nurse colleagues on the wards to deliver wound care to their patients as well as colleagues’ professional development. \nAcademically\, Dr Pagnamenta works at Northumbria University as a researcher where her main interests focus on leg ulceration\, clinical pathways\, and ways to prevent simple wounds from becoming chronic ulceration. \nAudience and criteria\nRegistered nurses with a degree in nursing or related subject\, who work in a clinical area where complex wound care and wound debridement is undertaken on a weekly basis\, and which supports learners. \nApplicants must identify a practice assessor in their organisation who is a designated Wound Care Health Professional. \nCourse dates\nThe attendance dates for the February 2025 cohort are: \n\nTuesday 4 February 2025\nWednesday 5 February 2025\n\nBooking\nTo book a place on this course go to Tickets at the bottom of the page.  Please note that this course has a pre-course assignment therefore tickets are available upto 4 weeks before the start of the course. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/methods-of-wound-debridement-february-2025/
LOCATION:Freeman Hospital (FH)\, Freeman Road\, High Heaton\,\, Newcastle upon Tyne\, Tyne and Wear\, NE7 7DN\, United Kingdom
CATEGORIES:Methods of Wound Debridement
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2024/11/Wound-Debridement-Photo.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250218T093000
DTEND;TZID=Europe/London:20250218T123000
DTSTAMP:20260406T051059
CREATED:20240828T134855Z
LAST-MODIFIED:20250429T144024Z
UID:10000088-1739871000-1739881800@skillsacademy.newcastle-hospitals.nhs.uk
SUMMARY:Targeted Treatments and Immunotherapy for Solid Tumours: Demystifying the Science - February 2025
DESCRIPTION:This course gives cancer nurses and trial staff the knowledge and confidence to discuss a wide range of targeted cancer treatments and immunotherapies with patients and colleagues. \nOverview\nThis course focuses on cancer biology and the science behind licensed treatments for solid tumours\, including monoclonal antibodies\, small molecule kinase inhibitors\, and immunotherapies. \nOver the course of two mornings\, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will guide you through the scientific concepts that underpin many of the most used targeted cancer treatments and immunotherapies for solid tumours. \nTreatments discussed include those that target cell communication pathways (e.g. EGFR and HER2-targeted treatments) and immune checkpoint inhibitors. Elaine also describes various molecular features of cancer that underpin many other new treatments. \nAudience\nThis content is ideal for research nurses\, clinical nurse specialists\, pharmacists\, and clinical trials coordinators. It may also interest other healthcare professionals wanting to improve their understanding of targeted treatments and immunotherapy. \nAs ever\, Elaine will use colourful illustrations and jargon-free explanations to help learners gain a broad understanding of the concepts covered. \nCourse delivery\nThe course comprises two morning sessions delivered online via Microsoft Teams as follows: \nSession One – Targeted cancer treatments – Tuesday 18 February 2025 09:30am – 12:30pm \nSession Two – Cancer immunotherapy – Tuesday 4 March 2024 09:30am – 12:30pm \n  \nSession One – Targeted cancer treatments\nTuesday 18 February 2025 – 09:30am – 12:30pm \nOver three presentations\, Dr Vickers guides us through the scientific concepts underpinning many of the most used targeted cancer treatments. Beginning with the bigger picture – what we can and can’t target – she then describes the mechanisms of action of the two main types of treatment: monoclonal antibodies that target cell surface proteins and small molecules that block kinases. \nMany of these treatments target cell communication pathways. Elaine will explain the function of these pathways in healthy cells and their defects in cancer cells. She’ll also describe why blocking these pathways sometimes works and sometimes doesn’t. \nLastly\, Elaine turns her attention to other targets and discusses when a targeted therapy or immunotherapy approach is more likely to work. \nTargeted cancer treatments – the current landscape \n\nDescribing the ‘Enabling Characteristics’ that allow cancer to develop and the ‘Hallmarks of Cancer Cells’ that drive cancer’s behaviour\nWhich can we target\, and how can we do it?\nThe pros and cons of small molecule inhibitors and monoclonal antibodies\n\nTreatments that target cell communication \n\nTargeting growth factor receptors such as EGFR\, HER2\, and MET\nInhibitors of growth factor receptor fusion proteins: ALK\, ROS1\, RET\, TRKA/B/C\nB-Raf & MEK inhibitors for BRAF-mutated cancers\nThe pros and cons of PI3K & mTOR inhibitors\nProgress in targeting Ras proteins\n\nOther targets and treatments \n\nThe mechanism of action and limitations of angiogenesis inhibitors\nPARP inhibitors for cancers with defects in homologous recombination\nCDK inhibitors for hormone-sensitive breast cancer\nWhen is targeted therapy or immunotherapy the best strategy?\n\nSession 2: Cancer immunotherapy \nTuesday 4 March 2025 – 09:30am – 12:30pm \nThe focus of this morning is on cancer’s relationship with the immune system and how this knowledge is being used to improve the outlook of people with various solid tumours. \nElaine describes how checkpoint inhibitors boost cancer-fighting T cells. She also highlights some of the lessons learned through the hundreds of clinical trials with checkpoint inhibitors that have taken place over the past decade. \nLastly\, Elaine explains how other forms of immunotherapy aim to create an anti-cancer immune response. \nAn introduction to immunotherapy \n\nA brief introduction to the immune system\nHow cancer’s relationship with the immune system changes over time\nHow the immune system can recognise and react to the presence of cancer in the body – the Cancer Immunity Cycle\nMechanisms of immune evasion by cancer cells\nAn overview of immunotherapy approaches and the importance of T cells\nReasons why immunotherapy sometimes does work and sometimes doesn’t\n\nImmunotherapy with checkpoint inhibitors \n\nIntroduction to checkpoint proteins on T cells\nDescribing the mechanism of action of checkpoint inhibitors\nSpot the difference: CTLA-4 and PD-1/P-L1 targeted checkpoint inhibitors\nSome of the many lessons learned from clinical trials with checkpoint inhibitors\n\nBiomarkers and combinations; other forms of immunotherapy \n\nDescribing the use of biomarkers to predict which patients will benefit from checkpoint inhibitors: what have we got and what’s coming?\nTreatment combinations to improve response rates\nNovel checkpoint inhibitors\nA broader look at immunotherapy strategies to create cancer-fighting T cells and the progress made in using them as treatments for solid tumours\nLooking to the future of immunotherapy for solid tumours\n\nDelegates will be given access to recordings of all sessions for three months after completion of the course. If you are unable to attend a session the recording will ensure you can review any content you have missed. \nCourse Lead\nDr Elaine Vickers PhD of Science Communicated Ltd\nDr Elaine Vickers\, PhD of Science Communicated Ltd has worked as a cancer educator for over twenty years and has previously acted as science communicator for three of the UK’s leading \nmedical research charities\, including four years in the Science Information team at Cancer Research UK. \nElaine is passionate about demystifying the science behind cancer biology and the latest cancer treatments such as kinase inhibitors\, monoclonal antibodies and immunotherapies. \nShe is experienced in teaching people with any level of scientific or medical knowledge from cancer patients through to medical oncologists translating complex and often overwhelming topics into easily digestible and understandable knowledge\, using colourful illustrations to explain scientific concepts. \nThe second edition of her book\, A Beginner’s Guide to Targeted Cancer Treatments – commended by the British Medical Association book awards is due out by the end of 2024. \nPayment\nPayments should where possible be made via the online booking system. \nIf you request an invoice at the point of booking\, invoice payment terms are strictly 30 days from the invoice date or 7 days before the start of the event\, or the date specified on the course booking page – whichever date is the earliest. \nCancellation and refunds policy\nShould you no longer be able to attend the event on the booked date\, please contact the Academy as we may be able to offer an alternative date subject to an admin charge. \nShould you still wish to cancel your booking\, you or your employer will be charged as per the fees outlined below. \n\n\n\nTimescale\nFee paying course\n\n\nOver 6 weeks\n£25 admin charge\n\n\n2 to 6 weeks\n50% of course fee\n\n\n0 to 2 weeks\n100% of course fee\n\n\n\nIf you do not attend on the day\, you will be charged the full cost of the event place. \nSee our Terms & Conditions and Cancellations & Refunds pages for more details. \nBooking\nTo book a place on this course go to Tickets at the bottom of the page. \nAt checkout you can make an online card payment or enter a coupon code to make alternative payment arrangements. \nAlternative payment arrangements include: \n\nrequesting an invoice (INVOICE)\,\nThe Newcastle upon Tyne Hospitals NHS Foundation Trust staff internal funding (NUTH) – you will need to complete a Trust study leave form.\n\nPlease see the Making payments & Coupons sections of the Help and FAQs.
URL:https://skillsacademy.newcastle-hospitals.nhs.uk/course/targeted-treatments-and-immunotherapy-for-solid-tumours-demystifying-the-science-february-2025/
LOCATION:Virtual delivery via MS Teams
ATTACH;FMTTYPE=image/jpeg:https://skillsacademy.newcastle-hospitals.nhs.uk/wp-content/uploads/2023/10/Gene-therapy-for-cancer-concept-illustration-slim-for-course.jpg
ORGANIZER;CN="Newcastle Hospitals Skills Academy":MAILTO:nuth.newcastlehospitalsskillsacademy@nhs.net
END:VEVENT
END:VCALENDAR